39 results about "Dopamine receptor antagonist" patented technology

Described herein are antipyschotic compounds of formula (I)wherein,A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S;Alk is (C1-4) alkylene optionally substituted with OH, methoxy, ethoxy, or F;Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic, or bicyclic heteroaromatic;R1 is hydrogen or (C1-4) alkyl optionally substituted with OH, OR3, or OCH2CH2OH,wherein R3 is (C1-2) alkyl;R2 is H, (C1-6) alkyl, halogen, fluorinated (C1-6) alkyl, OR4, SR4, NO2, CN, COR4, CONR5R6, SO2NR5R6, NR5R6, NR5COR4, NR5SO2R4, or optionally substituted phenyl,whereinR4 is hydrogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, or optionally substituted phenyl,R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl;Z is one or two substituents independently selected from hydrogen, halogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, SO2NR8R9, NR8SO2R7, NR8R9, or optionally substituted phenyl,whereinR7 is hydrogen, (C1-6) alkyl, fluorinated alkyl, or optionally substituted phenyl,R8 and R9 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl;and salts, solvates, and crystal forms thereof.Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorder, and pharmaceutical formulations of the compounds of formula (I).

The invention discloses application of a dopamine D1 receptor antagonist SCH39166 in preparation of a medicine for treating ocular pathological angiogenesis. The antagonist can inhibit ocular angiogenesis, has a remarkable effect on neovascularization of retinas, corneas and choroids, and can assist in treating angiogenesis ocular diseases.